KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Krystal Biotech, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$320.25+3.67 (+1.16%)

Close on Oct 19, 2026

Market cap: $9.82B
P/E (TTM): 40.1
Dividend yield: –

Krystal Biotech, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	496	345	358	162	341	268	188	104	50	1.92
Short-Term Investments	331	253	174	217	97	2.99	6.17	8.09	–	–
Cash & Short-Term Investments	828	598	532	379	438	271	194	112	50	1.92
Receivables	127	105	42	0	–	–	–	–	–	–
Inventory	40	27	6.99	0	–	–	–	–	–	–
Prepaid Expenses & Other	15	12	6.71	4.61	4.17	3.80	2.20	0.89	0.32	0.25
Other Current Assets	–	–	–	–	–	–	–	–	0.02	–
Total Current Assets	1,025	742	588	384	442	275	196	113	50	2.17
Property, Plant & Equipment	151	155	161	162	112	31	8.48	3.01	0.20	0.01
Gross Property, Plant & Equipment	182	177	174	168	117	33	9.33	3.18	0.23	0.02
Accumulated Depreciation	-31	-22	-13	-6.79	-4.21	-2.37	-0.85	-0.17	-0.03	0.00
Long-Term Investments	128	152	62	4.62	64	0	0.50	–	–	–
Operating Lease Right-of-Use Assets	7.24	6.28	7.03	8.04	7.23	3.30	2.71	1.10	–	–
Deferred Tax Assets	23	0	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.29	0.23	0.26	0.32	0.07	1.61	1.46	0.45	–	–
Total Assets	1,334	1,056	818	558	626	311	209	116	50	2.18
Accounts Payable	3.24	4.99	4.13	3.98	8.40	2.11	1.02	0.89	0.19	0.04
Current Portion of Leases	1.77	1.22	1.47	1.56	1.04	5.11	1.83	–	–	–
Other Current Liabilities	3.58	2.40	2.20	0.27	0.09	0.03	0.01	0.04	–	–
Total Current Liabilities	103	102	33	29	26	15	3.33	2.60	0.64	0.04
Long-Term Leases	7.57	6.04	6.62	7.37	6.98	3.31	2.78	–	–	–
Operating Lease Liabilities	9.34	7.26	8.09	8.93	8.02	3.95	3.26	1.40	–	–
Other Long-Term Liabilities	3.72	1.42	0	–	–	–	–	0.29	–	–
Total Liabilities	114	109	40	36	33	19	6.11	2.89	0.64	1.89
Preferred Stock	–	–	–	–	0	0	0	0	–	–
Common Stock	0	0	0	0	0	0	0	0	0	0
Additional Paid-In Capital	1,194	1,127	1,048	804	735	363	242	133	59	0.03
Retained Earnings	24	-181	-270	-281	-141	-71	-39	-20	-9.07	-1.15
Comprehensive Income & Other	1.14	-0.19	0.64	-0.73	-0.16	0.01	0.01	0.00	–	–
Shareholders' Equity	1,220	946	779	522	594	292	203	113	49	0.29
Total Equity	1,220	946	779	522	594	292	203	113	49	0.29
Total Liabilities & Equity	1,334	1,056	818	558	626	311	209	116	50	2.18
Shares Outstanding(shares)	29	29	28	26	25	20	17	14	10	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 44.9%
Net margin: 54.8%
Return on equity, FY2025: 18.9%

Financial strength

Current ratio: 8.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 335.8%

Valuation

P/E ratio: 40.1
Price to sales: 22.29
Price to book: 7.22
Dividend yield: –